Author

Mireia Margelí Vila

Universitat Autònoma de BarcelonaORCID 0000-0003-3594-4530Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Anna Martínez‐CardúsiD· 1 shared Cristina GuardiaiD· 1 shared Daniel Ortega-ÁlvareziD· 1 shared David Olivares-OsunaiD· 1 shared David Pérez-ParraiD· 1 shared David Tébar-GarcíaiD· 1 shared Elena Castillo-AgeaiD· 1 shared Elena Vinuesa-PitarchiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anna Martínez‐CardúsORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Discovery and evaluation of novel biomarkers reveal dasatinib as a potential treatment for a specific subtype of Triple-Negative Breast Cancer

Daniel Ortega-Álvarez, David Tébar-García, Marta Casado-Peláez, David Olivares-Osuna, Elena Castillo-Agea, Joan Balibrea-Rull, Rosa Angélica Barbella-Aponte, David Pérez-Parra, Eva Musulén, Cristina Guardia, Elena Vinuesa-Pitarch, Esther Sánchez López, Fátima Postigo-Corrales, Ester Ballana, Anna Martínez‐Cardús, , Verónica Rodilla

This study identifies BC-markers in TNBC, links them to poor prognosis and dasatinib sensitivity, suggesting TAGLN as a predictive biomarker for targeted therapy.

Cancer Research · Feb 11, 2026Peer-reviewedCancer Biology